3 MDMA-assisted PTSD therapy research papers by Lykos Therapeutics were retracted due to unethical conduct.

Psychopharmacology retracted three MDMA-assisted therapy research papers due to unethical conduct at one of the study sites. The affected studies were affiliated with Lykos Therapeutics, which sought FDA approval for MDMA-assisted therapy to treat PTSD. The FDA declined the application due to missing data and concerns over study design; Lykos stated the retracted papers were not part of their FDA application. The FDA has asked Lykos to conduct an additional clinical trial for its MDMA-assisted therapy.

August 12, 2024
8 Articles

Further Reading